|1.||Goldman, M: 3 articles (01/2003 - 01/2003)|
|2.||Fozard, J R: 2 articles (01/2004 - 12/2001)|
|3.||Keating, E T: 2 articles (01/2003 - 01/2003)|
|4.||Mazzoni, L: 1 article (01/2004)|
|5.||Buescher, H: 1 article (01/2004)|
|6.||Farr, D C: 1 article (01/2004)|
|7.||Halpin, D: 1 article (01/2003)|
|8.||Calverley, P: 1 article (01/2003)|
|9.||Celli, B: 1 article (01/2003)|
|10.||Alderfer, V: 1 article (01/2003)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2003 - "While the results of this study failed to demonstrate sustained efficacy with sibenadet therapy, they do indicate the value of symptom assessment in the clinical evaluation of new drugs for the treatment of COPD."
01/01/2003 - "This study enrolled patients with symptomatic, smoking-related COPD, randomized to receive sibenadet or placebo for a 52-week treatment period. "
01/01/2003 - "The dual sensory nerve modulation and bronchodilator effects of sibenadet have been demonstrated in initial dose-ranging studies of patients with COPD and large-scale clinical evaluation has now been completed. "
01/01/2003 - "These results provided a compelling rationale for the initiation of a clinical development programme with sibenadet for the treatment of COPD."
01/01/2003 - "These multicentre, double-blind, placebo-controlled studies recruited over 2000 patients with stable COPD, randomized to receive sibenadet (500 microg) or placebo, pressurized metered-dose inhaler (pMDI) (three times daily) for a period of 12 or 26 weeks. "
01/01/2003 - "In the course of these studies it was demonstrated that sibenadet, through activation of D2-receptors, inhibited discharge of rapidly adapting receptors and was effective in reducing reflex-induced tachypnoea, mucus production and cough in the dog. "
01/01/2003 - "Sibenadet efficacy was determined by assessing symptomatic changes, as defined by the novel assessment tool, the Breathlessness, Cough and Sputum Scale (BCSS). "
01/01/2003 - "Investigation in animal models of key chronic obstructive pulmonary disease (COPD) symptoms has demonstrated that sibenadet effectively inhibits sensory nerve activity, thereby reducing reflex cough, mucus production and tachypnoea. "
01/01/2003 - "Viozan (sibenadet HCl, AR-C68397AA) is a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist, developed specifically to treat the key symptoms of chronic obstructive pulmonary disease (COPD), breathlessness, cough and sputum. "
|4.||Asthma (Bronchial Asthma)
|4.||Dopamine Receptors (Dopamine Receptor)
|5.||Methacholine Chloride (Methacholine)
|1.||Metered Dose Inhalers (Metered Dose Inhaler)